Opportunity, I am not wrong about RPC. The stock is only where it is because management has pumped the stock with unreasonable estimates of sales and potential. Onko Sure is no better than RECAF and will never succeed as a general screen. No one is using it to monitor cancer either. It just has no market in the USA just like Dog RECAF has no market.
You will need to check back with RPC when their house of cards folds later this year.
News 
Market Data 
Discover 
